Pyxis Oncology, Inc.
NASDAQ:PYXSBiotechnology
+$0.11 today
- Market cap
- $168.65M
- Beta
- 1.43
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.29
Volume 0.75M
Average 0.50M
PYXS Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Pyxis Oncology, Inc.NASDAQ: PYXS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $459K fell 16.8% year over year, behind the +82.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 84.1% from the prior quarter. Over 3 fiscal years it compounded at +85.3% a year.
Context
- Depreciation & amortization amounted to 32.6% of revenue in FY2025, up 14.1 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -16.8% toward the trailing-twelve-month pace of +82.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 4.51M USD
- Year-over-year change
- +51.3%
- 4-year CAGR
- +62.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.51M | +51.3% |
| FY2024 | 2024-12-31 | 2.98M | +54.7% |
| FY2023 | 2023-12-31 | 1.93M | +171.8% |
| FY2022 | 2022-12-31 | 709K | +9.6% |
| FY2021 | 2021-12-31 | 647K | — |
Depreciation & Amortization vs competitors
How PYXS compares with its peers on the latest reported figures
- PYXS's LTM Mar 2026 depreciation & amortization of $4.42M is the 4th highest of the 10 companies compared; the peer median is $3.13M.
- Its year-over-year change of +82.7% is the 2nd highest of 10, against a peer median of +0.0%.
- Depreciation & amortization amounts to 31.9% of revenue for PYXS, versus a peer median of 19.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.54M | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $7.3M | +0.4% | -3.6% | 362.3% | |
| LTM Mar 2026 | $4.93M | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $4.42M | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $3.98M | -12.6% | -13.1% | 10.9% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.79M | -10.3% | +0.1% | 9.9% | |
| LTM Mar 2026 | $786.79K | +70.5% | +36.1% | — | |
| LTM Mar 2026 | $416K | +0.0% | +17.0% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $56K | +211.1% | — | — |
| Peer median (excluding PYXS) | $3.13M | +0.0% | +0.1% | 19.4% | |
Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 16.15M | 13.86M |
| Cost of Revenue | 0 | 0 | 0 | 475K | 2.39M |
| Gross Profit | 0 | 0 | 0 | 15.67M | 11.47M |
| Gross Margin | — | — | — | 97.1% | 82.8% |
| Research & Development | 51.05M | 86.13M | 49.59M | 58.75M | 73.7M |
| Selling, General & Admin | 18.66M | 37.35M | 32.61M | 25.42M | 22.19M |
| Operating Expenses | 69.72M | 123.48M | 82.2M | 105.13M | 95.89M |
| Depreciation & Amortization | 647K | 709K | 1.93M | 2.98M | 4.51M |
| EBITDA | (75.33M) | (120.01M) | (71.86M) | (65.51M) | (73.72M) |
| EBITDA Margin | — | — | — | -405.8% | -532.0% |
| Operating Income | (69.72M) | (123.48M) | (82.2M) | (89.46M) | (84.42M) |
| Operating Margin | — | — | — | -554.1% | -609.2% |
| Interest Income | 23K | 2.76M | 6.63M | 7.04M | 3.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6.26M) | 2.76M | 8.41M | 9.97M | 6.19M |
| Income Before Tax | (75.98M) | (120.72M) | (73.79M) | (79.5M) | (78.24M) |
| Pre-Tax Margin | — | — | — | -492.4% | -564.5% |
| Income Tax Expense | 0 | 0 | 0 | (2.16M) | 1.39M |
| Net Income | (75.98M) | (120.72M) | (73.79M) | (77.33M) | (79.62M) |
| Net Margin | — | — | — | -478.9% | -574.5% |
| EPS (Basic) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| EPS (Diluted) | (2.53) | (3.57) | (1.85) | (1.32) | (1.28) |
| Weighted Avg Shares | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M |
| Weighted Avg Shares (Diluted) | 32.22M | 33.03M | 39.9M | 58.45M | 62.14M |
Pyxis Oncology, Inc.
NASDAQ:PYXS
Intrinsic Alpha fair value
Locked
Current Price
$1.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.